KR20130101047A - 신규한 항원 결합 단백질 - Google Patents
신규한 항원 결합 단백질 Download PDFInfo
- Publication number
- KR20130101047A KR20130101047A KR1020137008415A KR20137008415A KR20130101047A KR 20130101047 A KR20130101047 A KR 20130101047A KR 1020137008415 A KR1020137008415 A KR 1020137008415A KR 20137008415 A KR20137008415 A KR 20137008415A KR 20130101047 A KR20130101047 A KR 20130101047A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen binding
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000025171 antigen binding proteins Human genes 0.000 title claims abstract description 409
- 108091000831 antigen binding proteins Proteins 0.000 title claims abstract description 409
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims abstract description 217
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 137
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 97
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 37
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 37
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 28
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 28
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 28
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 24
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 24
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 24
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 23
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 23
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 23
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 23
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 23
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 21
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 claims abstract description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 304
- 150000007523 nucleic acids Chemical class 0.000 claims description 178
- 230000027455 binding Effects 0.000 claims description 148
- 102000039446 nucleic acids Human genes 0.000 claims description 110
- 108020004707 nucleic acids Proteins 0.000 claims description 110
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 201000011510 cancer Diseases 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 241000282414 Homo sapiens Species 0.000 claims description 73
- 125000000539 amino acid group Chemical group 0.000 claims description 71
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 239000013604 expression vector Substances 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 108020004414 DNA Proteins 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 201000000849 skin cancer Diseases 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 17
- 101150023212 fut8 gene Proteins 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 208000006994 Precancerous Conditions Diseases 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 13
- 239000000539 dimer Substances 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 102000023732 binding proteins Human genes 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- -1 antibodies Proteins 0.000 abstract description 25
- 108091033319 polynucleotide Proteins 0.000 abstract description 19
- 102000040430 polynucleotide Human genes 0.000 abstract description 19
- 239000002157 polynucleotide Substances 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 177
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 131
- 230000000694 effects Effects 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 61
- 241001529936 Murinae Species 0.000 description 60
- 239000000427 antigen Substances 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 45
- 102000036639 antigens Human genes 0.000 description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 102000005962 receptors Human genes 0.000 description 45
- 108020003175 receptors Proteins 0.000 description 45
- 239000003112 inhibitor Substances 0.000 description 41
- 239000002246 antineoplastic agent Substances 0.000 description 37
- 201000010099 disease Diseases 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 35
- 239000012634 fragment Substances 0.000 description 31
- 230000006870 function Effects 0.000 description 30
- 230000005764 inhibitory process Effects 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 239000012636 effector Substances 0.000 description 27
- 239000003446 ligand Substances 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 26
- 238000003556 assay Methods 0.000 description 26
- 102400000058 Neuregulin-1 Human genes 0.000 description 25
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 23
- 102000057750 human ERBB3 Human genes 0.000 description 23
- 108090000556 Neuregulin-1 Proteins 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 21
- 102000001301 EGF receptor Human genes 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 230000000670 limiting effect Effects 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 20
- 108060006698 EGF receptor Proteins 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 230000026731 phosphorylation Effects 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- 238000011579 SCID mouse model Methods 0.000 description 16
- 229940127089 cytotoxic agent Drugs 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 208000032839 leukemia Diseases 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 206010025323 Lymphomas Diseases 0.000 description 14
- 229940034982 antineoplastic agent Drugs 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 14
- 230000004075 alteration Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 108010073807 IgG Receptors Proteins 0.000 description 12
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 12
- 230000003442 weekly effect Effects 0.000 description 12
- 206010065553 Bone marrow failure Diseases 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 11
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 11
- 238000000540 analysis of variance Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 108091008611 Protein Kinase B Proteins 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000003527 eukaryotic cell Anatomy 0.000 description 8
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 108010006654 Bleomycin Proteins 0.000 description 7
- 108010092160 Dactinomycin Proteins 0.000 description 7
- 102000009465 Growth Factor Receptors Human genes 0.000 description 7
- 108010009202 Growth Factor Receptors Proteins 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
- 229960005277 gemcitabine Drugs 0.000 description 7
- 229940020967 gemzar Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 7
- 201000002364 leukopenia Diseases 0.000 description 7
- 231100001022 leukopenia Toxicity 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 230000006820 DNA synthesis Effects 0.000 description 6
- 206010014733 Endometrial cancer Diseases 0.000 description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 206010057249 Phagocytosis Diseases 0.000 description 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 6
- 229940122803 Vinca alkaloid Drugs 0.000 description 6
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 6
- 229940100198 alkylating agent Drugs 0.000 description 6
- 239000002168 alkylating agent Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 150000004141 diterpene derivatives Chemical class 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 6
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 6
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 5
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 5
- 229960004562 carboplatin Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 229960000640 dactinomycin Drugs 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 229960005420 etoposide Drugs 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000000833 heterodimer Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960001428 mercaptopurine Drugs 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 229960003087 tioguanine Drugs 0.000 description 5
- 229960000303 topotecan Drugs 0.000 description 5
- 229960001612 trastuzumab emtansine Drugs 0.000 description 5
- 229960004528 vincristine Drugs 0.000 description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- 241000282836 Camelus dromedarius Species 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 102000019298 Lipocalin Human genes 0.000 description 4
- 108050006654 Lipocalin Proteins 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 241000282567 Macaca fascicularis Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 101800000675 Neuregulin-2 Proteins 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 102100022668 Pro-neuregulin-2, membrane-bound isoform Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 229940127093 camptothecin Drugs 0.000 description 4
- 229960005243 carmustine Drugs 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229960004630 chlorambucil Drugs 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 229960003901 dacarbazine Drugs 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000005734 heterodimerization reaction Methods 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229960000639 pazopanib Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229960003787 sorafenib Drugs 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229960001278 teniposide Drugs 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 238000007492 two-way ANOVA Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 4
- 229960003048 vinblastine Drugs 0.000 description 4
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 4
- 229960002066 vinorelbine Drugs 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- 108090000342 C-Type Lectins Proteins 0.000 description 3
- 102000003930 C-Type Lectins Human genes 0.000 description 3
- 241000251730 Chondrichthyes Species 0.000 description 3
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 3
- 102000003915 DNA Topoisomerases Human genes 0.000 description 3
- 108090000323 DNA Topoisomerases Proteins 0.000 description 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 3
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 3
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 102000000470 PDZ domains Human genes 0.000 description 3
- 108050008994 PDZ domains Proteins 0.000 description 3
- 108010079855 Peptide Aptamers Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 108091005682 Receptor kinases Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102000014400 SH2 domains Human genes 0.000 description 3
- 108050003452 SH2 domains Proteins 0.000 description 3
- 102000000395 SH3 domains Human genes 0.000 description 3
- 108050008861 SH3 domains Proteins 0.000 description 3
- 108091006627 SLC12A9 Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 102100024554 Tetranectin Human genes 0.000 description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002938 bexarotene Drugs 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000009702 cancer cell proliferation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 108020001096 dihydrofolate reductase Proteins 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229960002087 pertuzumab Drugs 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108700042226 ras Genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002795 scorpion venom Substances 0.000 description 3
- 238000011519 second-line treatment Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 108010013645 tetranectin Proteins 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 230000004565 tumor cell growth Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- FOVRGQUEGRCWPD-UHFFFAOYSA-N (5aR)-9t-beta-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(OC3C(C(O)C(O)C(CO)O3)O)C3C2C(OC3)=O)=C1 FOVRGQUEGRCWPD-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- YVCVYCSAAZQOJI-JHQYFNNDSA-N 4'-demethylepipodophyllotoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YVCVYCSAAZQOJI-JHQYFNNDSA-N 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 description 2
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 102400001242 Betacellulin Human genes 0.000 description 2
- 101800001382 Betacellulin Proteins 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010059013 Chaperonin 10 Proteins 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 201000002847 Cowden syndrome Diseases 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000002090 Fibronectin type III Human genes 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 2
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 2
- 108030003815 Inositol 3-kinases Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 101800000673 Neuregulin-3 Proteins 0.000 description 2
- 101800002641 Neuregulin-4 Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 102100022659 Pro-neuregulin-3, membrane-bound isoform Human genes 0.000 description 2
- 102100022658 Pro-neuregulin-4, membrane-bound isoform Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 102100023132 Transcription factor Jun Human genes 0.000 description 2
- 241000223259 Trichoderma Species 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001399 anti-metabolic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001946 anti-microtubular Effects 0.000 description 2
- 229940044684 anti-microtubule agent Drugs 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011143 bone giant cell tumor Diseases 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 208000018925 gastrointestinal mucositis Diseases 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 238000000892 gravimetry Methods 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000003668 hormone analog Substances 0.000 description 2
- 239000002944 hormone and hormone analog Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 201000009857 isthmus cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- 229960002450 ofatumumab Drugs 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000021014 regulation of cell growth Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000004654 triazenes Chemical class 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- VSJKWCGYPAHWDS-HXUWFJFHSA-N (r)-camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-HXUWFJFHSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- JNSWIYCWZPFQQF-UHFFFAOYSA-N 3-(carboxyamino)-2-hydroxy-3-phenylpropanoic acid Chemical compound OC(=O)C(O)C(NC(O)=O)C1=CC=CC=C1 JNSWIYCWZPFQQF-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- IMXHGCRIEAKIBU-UHFFFAOYSA-N 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC3)C(=O)OC)C2=N1 IMXHGCRIEAKIBU-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NBTLVNGLNYCJIL-QUIPCFFLSA-N 4-amino-1-[(2R,3S,4R,5R)-3-(10,10-difluorodecoxy)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound FC(CCCCCCCCCO[C@@]1([C@@H](O[C@@H]([C@H]1O)CO)N1C(=O)N=C(N)C=C1)O)F NBTLVNGLNYCJIL-QUIPCFFLSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- ZLOLCGXDJBXQCN-UHFFFAOYSA-N 5-[[4-[(2,3-dimethylindazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1CNC(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 ZLOLCGXDJBXQCN-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- CZNJCCVKDVCRKF-UHFFFAOYSA-N Benzyl sulfate Chemical compound OS(=O)(=O)OCC1=CC=CC=C1 CZNJCCVKDVCRKF-UHFFFAOYSA-N 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000012609 Cowden disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100030323 Epigen Human genes 0.000 description 1
- 108010016906 Epigen Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 102000005385 Intramolecular Transferases Human genes 0.000 description 1
- 108010031311 Intramolecular Transferases Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000570861 Mandragora autumnalis Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 108010046068 N-Acetyllactosamine Synthase Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241001147844 Streptomyces verticillus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 102100026160 Tomoregulin-2 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 101100175600 Zea mays SH2 gene Proteins 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940088547 cosmegen Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-L cyclobutane-1,1-dicarboxylate(2-) Chemical compound [O-]C(=O)C1(C([O-])=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-L 0.000 description 1
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 238000011188 deamidation reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 102000035175 foldases Human genes 0.000 description 1
- 108091005749 foldases Proteins 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 102000013069 gamma-Crystallins Human genes 0.000 description 1
- 108010079934 gamma-Crystallins Proteins 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108010067006 heat stable toxin (E coli) Proteins 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000056549 human Fv Human genes 0.000 description 1
- 108700005872 human Fv Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- WFFQYWAAEWLHJC-UHFFFAOYSA-N mercaptopurine hydrate Chemical compound O.S=C1NC=NC2=C1NC=N2 WFFQYWAAEWLHJC-UHFFFAOYSA-N 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- VDOCQQKGPJENHJ-UHFFFAOYSA-N methyl n-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OC)=CC=C1C1=NC(N2CCOCC2)=C(C=NN2C3CCN(CC=4C=NC=CC=4)CC3)C2=N1 VDOCQQKGPJENHJ-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003606 oligomerizing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229940063179 platinol Drugs 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095374 tabloid Drugs 0.000 description 1
- 229940099419 targretin Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YASDAMSCJQDYKJ-UHFFFAOYSA-N tricos-7-ene-2,5,15,18,21-pentone Chemical compound CCC(=O)CCC(=O)CCC(=O)CCCCCCC=CCC(=O)CCC(C)=O YASDAMSCJQDYKJ-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37984010P | 2010-09-03 | 2010-09-03 | |
| US61/379,840 | 2010-09-03 | ||
| US201161440460P | 2011-02-08 | 2011-02-08 | |
| US61/440,460 | 2011-02-08 | ||
| PCT/US2011/050322 WO2012031198A2 (en) | 2010-09-03 | 2011-09-02 | Novel antigen binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130101047A true KR20130101047A (ko) | 2013-09-12 |
Family
ID=45773540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137008415A Withdrawn KR20130101047A (ko) | 2010-09-03 | 2011-09-02 | 신규한 항원 결합 단백질 |
Country Status (21)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ600262A (en) | 2009-12-22 | 2013-06-28 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| PH12013500333A1 (en) | 2010-08-20 | 2013-04-22 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2013078191A1 (en) | 2011-11-23 | 2013-05-30 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| ES2758433T3 (es) | 2011-12-05 | 2020-05-05 | Novartis Ag | Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3) |
| UY34488A (es) * | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos dirigidos al receptor de factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio iii y dominio iv del her3 |
| US20130196880A1 (en) * | 2012-01-27 | 2013-08-01 | Ventana Medical Systems, Inc. | Patterned devices and methods for detecting analytes |
| MA38165A1 (fr) * | 2012-11-08 | 2018-07-31 | Hoffmann La Roche | Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3 |
| SG11201502534UA (en) | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3036259B1 (en) | 2013-10-04 | 2018-02-21 | Roche Diagnostics GmbH | Antibodies specifically binding to her3 |
| DK3805268T3 (da) | 2014-02-28 | 2025-01-20 | Merus Nv | Antistof, der binder erbb-2 og erbb-3 |
| US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| CA2944895A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
| RU2695220C2 (ru) | 2014-06-30 | 2019-07-22 | Тарведа Терапьютикс, Инк. | Нацеленные конъюгаты и частицы и их составы |
| US11254933B2 (en) * | 2014-07-14 | 2022-02-22 | The Regents Of The University Of California | CRISPR/Cas transcriptional modulation |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| US11160871B2 (en) | 2015-10-28 | 2021-11-02 | Tarveda Therapeutics, Inc. | SSTR-targeted conjugates and particles and formulations thereof |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| CA3011949A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| CN121086057A (zh) * | 2016-06-10 | 2025-12-09 | 德国癌症研究公共权益基金会 | 膜联蛋白的核心结构域及其在抗原递送和接种中的用途 |
| CN106543286A (zh) * | 2016-12-07 | 2017-03-29 | 上海邦耀生物科技有限公司 | 一种去岩藻糖抗her2抗体及其应用 |
| EP3600413A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| KR102744809B1 (ko) | 2017-05-17 | 2024-12-23 | 메뤼스 엔.페. | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| JP2021514662A (ja) * | 2018-03-08 | 2021-06-17 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｔｉｐ−１抗体及びその使用 |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| KR20220069935A (ko) * | 2019-09-27 | 2022-05-27 | 아게누스 인코포레이티드 | 이종이량체 단백질 |
| US20250243261A1 (en) * | 2022-04-08 | 2025-07-31 | Cz Biohub Sf, Llc | Antibody compositions and optimization methods |
| CN116286828B (zh) * | 2023-05-12 | 2023-08-18 | 中国人民解放军军事科学院军事医学研究院 | 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用 |
| CN117903311B (zh) * | 2024-03-20 | 2024-10-25 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
| CN120352624B (zh) * | 2025-06-25 | 2025-08-26 | 北京溯本源和生物科技有限公司 | 一种用于hpv18型e7蛋白检测的单克隆抗体组合及应用 |
Family Cites Families (235)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US6639061B1 (en) | 1999-07-07 | 2003-10-28 | Isis Pharmaceuticals, Inc. | C3′-methylene hydrogen phosphonate oligomers and related compounds |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| WO1996014864A1 (en) | 1994-11-09 | 1996-05-23 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| CA2589421C (en) | 1996-03-27 | 2012-12-18 | Genentech, Inc. | Erbb3 antibodies |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| CN1202247C (zh) | 1996-07-12 | 2005-05-18 | 基因技术股份有限公司 | 嵌合异源多亚基粘附素 |
| US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| US6723694B1 (en) | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
| US6416168B1 (en) | 1997-07-15 | 2002-07-09 | Silverbrook Research Pty Ltd | Pump action refill ink jet printing mechanism |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| AU2003203831B2 (en) | 1998-02-04 | 2006-08-10 | Genentech, Inc. | Use of heregulin as an epithelial cell growth factor |
| DE69920405T2 (de) | 1998-02-04 | 2006-01-05 | Genentech, Inc., South San Francisco | Verwendung des heregulins als epithelzellenwachstumsfaktor |
| US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| ES2389387T3 (es) | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Polipéptidos homólogos de VEGF y de BMP1 |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| AU2004200705A1 (en) | 1998-05-15 | 2004-03-18 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| CA2345899A1 (en) | 1998-11-07 | 2000-05-18 | Genentech, Inc. | Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1169352A4 (en) * | 1999-04-14 | 2005-05-04 | Smithkline Beecham Corp | ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US6710186B2 (en) | 1999-06-14 | 2004-03-23 | Wisconsin Alumni Research Foundation | Oligomers and polymers of di-substituted cyclic imino carboxylic acids |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| BRPI0012198B8 (pt) | 1999-06-25 | 2021-05-25 | Genentech Inc | anticorpos humanizados, composição e imunoconjugado |
| KR20020012292A (ko) | 1999-06-25 | 2002-02-15 | 제넨테크, 인크. | 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7732157B1 (en) | 1999-09-30 | 2010-06-08 | Tumor Biology Investment Group | Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| MXPA02006843A (es) | 2000-01-12 | 2004-04-05 | Ventana Med Syst Inc | Metodo para cuantificar una proteina por analisis de imagenes. |
| DK1666052T3 (da) | 2000-02-16 | 2011-09-12 | Genentech Inc | Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| AU2007216733A1 (en) | 2000-04-11 | 2007-09-27 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6277640B1 (en) | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| ATE356575T1 (de) | 2000-11-24 | 2007-04-15 | Freudenberg Carl Kg | Bodenwischer |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AU2008200400B2 (en) | 2001-01-17 | 2012-06-07 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
| AU2002240338C1 (en) | 2001-02-12 | 2007-05-17 | Medarex, Inc. | Human monoclonal antibodies to FC alpha receptor (CD89) |
| JP4398644B2 (ja) | 2001-04-06 | 2010-01-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | ＥｒｂＢ界面ペプチド擬態およびその使用方法 |
| US20040116330A1 (en) | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| JP2005505749A (ja) | 2001-05-21 | 2005-02-24 | アクララ バイオサイエンシーズ， インコーポレイテッド | タンパク質を分析するための方法および組成物 |
| US7745398B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1397837A2 (en) | 2001-06-21 | 2004-03-17 | Akzo Nobel N.V. | Manufacturing a solar cell foil connected in series via a temporary substrate |
| US7125680B2 (en) | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| DE10137374A1 (de) | 2001-07-31 | 2003-02-27 | Ipk Inst Fuer Pflanzengenetik | Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen |
| US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
| AU2008200654B2 (en) | 2001-08-09 | 2010-04-29 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Inhibitors of HER3 activity |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2480099C (en) | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| JP4132912B2 (ja) | 2002-03-26 | 2008-08-13 | 日東電工株式会社 | ゲル電解質とその製造方法とその利用 |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| WO2003102132A2 (en) | 2002-04-26 | 2003-12-11 | Genetech, Inc. | Non-affinity purification of proteins |
| US20040229293A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20040229299A1 (en) | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| AU2003273218C1 (en) | 2002-07-15 | 2019-01-17 | F. Hoffmann - La Roche Ag | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| DE60329194D1 (de) | 2002-07-25 | 2009-10-22 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| GB0225282D0 (en) | 2002-10-31 | 2002-12-11 | Astrazeneca Ab | assay |
| WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP1613661B1 (en) | 2003-04-04 | 2011-06-29 | Université de Lausanne | Peptabody for cancer treatment |
| US7189694B2 (en) | 2003-04-18 | 2007-03-13 | University Of Florida Research Foundation, Inc. | Inhibitors of autophosphorylation protein kinases |
| EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
| DE602004019919D1 (de) | 2003-06-06 | 2009-04-23 | Genentech Inc | Modulation der wechselwirkung zwischen hgf-beta-kette und c-met |
| US20040254108A1 (en) | 2003-06-13 | 2004-12-16 | Jing Ma | Preparation and application of anti-tumor bifunctional fusion proteins |
| WO2005001048A2 (en) | 2003-06-13 | 2005-01-06 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| US20050232931A1 (en) | 2003-06-13 | 2005-10-20 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| US6836094B1 (en) | 2003-07-01 | 2004-12-28 | International Truck Intellectual Property Company, Llc | Motor vehicle battery disconnect switch circuits |
| US7531649B2 (en) | 2003-07-18 | 2009-05-12 | The Regents Of The University Of California | Aptamers to human epidermal growth factor receptor-3 |
| CA2531595C (en) | 2003-07-28 | 2015-12-08 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| WO2005013804A2 (en) | 2003-08-05 | 2005-02-17 | Euro-Celtique S.A. | ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE |
| WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| CA2535510C (en) | 2003-08-11 | 2013-10-15 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| EP1681983A4 (en) | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
| US20050130246A1 (en) | 2003-10-27 | 2005-06-16 | Hossein Salimi-Moosavi | Detecting human anti-therapeutic antibodies |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| US7754441B2 (en) | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| JP4658967B2 (ja) | 2003-12-24 | 2011-03-23 | ジェネンテック， インコーポレイテッド | 造血系起源の腫瘍の治療のための組成物と方法 |
| US8323987B2 (en) | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
| JP2007528725A (ja) | 2004-02-20 | 2007-10-18 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 結合ペルオキシダーゼ模倣物及びその使用 |
| CA2564538A1 (en) | 2004-04-22 | 2005-12-01 | Oregon Health And Science University | Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors |
| CN1997382A (zh) | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US20070197430A1 (en) | 2004-06-24 | 2007-08-23 | Jonathan Baell | Conjugates And Therapeutic Uses Thereof |
| ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| AU2005294347A1 (en) | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
| CA2587617C (en) | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| CA2587926A1 (en) | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Bicyclic inhibitors or rho kinase |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| EP2281841A3 (en) * | 2004-12-03 | 2013-10-23 | Merck Sharp & Dohme Corp. | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
| JP2008523073A (ja) | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2601700A1 (en) | 2004-12-21 | 2006-06-29 | Cell Signaling Technology, Inc. | Protein phosphorylation in egfr-signaling pathways |
| US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| US7557181B2 (en) | 2005-01-11 | 2009-07-07 | Molecular Logix, Inc. | Pan-HER antagonists and methods of use |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| WO2006084018A2 (en) | 2005-02-02 | 2006-08-10 | Monogram Biosciences, Inc. | Methods for determining responsiveness to cancer therapy |
| KR101569300B1 (ko) | 2005-02-07 | 2015-11-13 | 로슈 글리카트 아게 | Ｅｇｆｒ 에 결합하는 항원 결합 분자, 이를 코딩하는 벡터, 및 그의 용도 |
| US7718626B2 (en) | 2005-02-17 | 2010-05-18 | University Of Maryland, Baltimore | ErbB3 binding protein compositions and methods of use |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| JP2008535795A (ja) | 2005-03-07 | 2008-09-04 | ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー | チロシンキナーゼインヒビター組成物、並びに疾患の治療におけるそれらの製造及び使用のための方法 |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| AU2006232920B2 (en) | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| EP1913160A2 (en) | 2005-07-29 | 2008-04-23 | Bayer Healthcare LLC | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| CN103204935B (zh) | 2005-08-26 | 2014-12-10 | 罗氏格黎卡特股份公司 | 具有改变的细胞信号传导活性的修饰的抗原结合分子 |
| CA2624086A1 (en) | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| US20090252681A1 (en) | 2005-10-11 | 2009-10-08 | Ablynx N.V. | Nanobodies and Polypeptides Against EGFR and IGF-IR |
| US20110052570A1 (en) | 2005-10-26 | 2011-03-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
| EP1792622A1 (en) | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| EP1963368B3 (en) | 2005-12-13 | 2020-06-10 | Eli Lilly And Company | Anti-il-17 antibodies |
| EP1800695A1 (en) | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| JP2009525048A (ja) | 2006-02-01 | 2009-07-09 | ザ ジョンズ ホプキンス ユニバーシティー | 腫瘍性障害または感染症に対する免疫学的予防法または免疫療法のためのポリペプチド−核酸複合体 |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| WO2007115571A2 (en) | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
| US20080038271A1 (en) | 2006-06-05 | 2008-02-14 | Amler Lukas C | Extending survival of cancer patients with elevated levels of EGF or TGF-alpha |
| CN101627053A (zh) * | 2006-06-12 | 2010-01-13 | 西福根有限公司 | 泛细胞表面受体特异的治疗剂 |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| WO2008019394A2 (en) | 2006-08-11 | 2008-02-14 | The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services | Methods for treatment and diagnosis of psychiatric disorders |
| US8936780B2 (en) | 2006-08-30 | 2015-01-20 | Advanced Cardiovascular Systems, Inc. | Stimuli responsive polyester amide particles |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
| MX2009003048A (es) | 2006-09-21 | 2009-09-07 | Prometheus Lab Inc | Disposiciones a base de anticuerpo para detectar transductores de multiple señal en celulas circulantes raras. |
| US20080076139A1 (en) | 2006-09-21 | 2008-03-27 | Sharat Singh | Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| EP2092075A2 (en) | 2006-11-06 | 2009-08-26 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
| AU2007353412A1 (en) | 2006-11-21 | 2008-11-20 | Fox Chase Cancer Center | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
| EP2518508A1 (en) | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
| JP2010511382A (ja) | 2006-12-01 | 2010-04-15 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 癌関連タンパク質キナーゼ |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
| US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CA2675014C (en) | 2007-01-17 | 2016-03-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| AR065803A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| CA2681790A1 (en) | 2007-03-30 | 2008-10-09 | F. Hoffmann-La Roche Ag | Composition of labeled and non-labeled monoclonal antibodies |
| AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| FR2915115B1 (fr) | 2007-04-23 | 2010-09-10 | Sames Technologies | Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe |
| AU2008259930B2 (en) | 2007-06-01 | 2014-05-29 | The Regents Of The University Of California | Multigene prognostic assay for lung cancer |
| BRPI0812777A2 (pt) | 2007-06-06 | 2014-12-02 | Hoffmann La Roche | Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir |
| US20100183504A1 (en) | 2007-06-14 | 2010-07-22 | Fanqing Frank Chen | Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics |
| WO2009003082A2 (en) | 2007-06-26 | 2008-12-31 | Vanderbilt University | Immunological compositions as cancer biomarkers and/or therapeutics |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| CA3113365A1 (en) | 2007-07-09 | 2009-01-15 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| BRPI0813583A2 (pt) | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
| WO2009023266A1 (en) | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
| US20120047586A9 (en) | 2007-10-24 | 2012-02-23 | Otsuka Chemical Co., Ltd | Polypeptide having enhanced effector function |
| EP2602623B1 (en) | 2008-02-25 | 2015-09-16 | Nestec S.A. | Mehtod for the detection of intracellular truncated receptors |
| AU2009221729A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and HER antagonists |
| EP2106806A1 (en) | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| EP2860260A1 (en) | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| WO2009134870A1 (en) | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| CA2727278A1 (en) | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| US8445219B2 (en) | 2008-07-25 | 2013-05-21 | Merck Patent Gmbh | Method of determination of receptor binding saturation effected by monoclonal antibodies |
| US8056451B2 (en) | 2008-07-28 | 2011-11-15 | Irwin Industrial Tool Company | Locking pliers |
| US20100033482A1 (en) | 2008-08-11 | 2010-02-11 | Interactive Relighting of Dynamic Refractive Objects | Interactive Relighting of Dynamic Refractive Objects |
| AU2009281721A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| US8084222B2 (en) | 2008-09-26 | 2011-12-27 | Eureka Therapeutics, Inc. | Methods for generating host cells |
| CN102753193A (zh) | 2008-10-31 | 2012-10-24 | 比奥根艾迪克Ma公司 | Light靶向分子及其用途 |
| EP3622968A1 (en) | 2008-10-31 | 2020-03-18 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| US20100169729A1 (en) | 2008-12-30 | 2010-07-01 | Datta Shamanna M | Enabling an integrated memory controller to transparently work with defective memory devices |
| EP2380025B1 (en) | 2009-01-14 | 2013-09-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ratio based biomarkers and methods of use thereof |
| BRPI1007321A2 (pt) | 2009-01-15 | 2018-07-10 | Laboratory Corp America Holdings | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. |
| SG172984A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-2 expression |
| PT3903829T (pt) | 2009-02-13 | 2023-06-02 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
| EP2401621B1 (en) | 2009-02-24 | 2013-08-14 | Roche Diagnostics GmbH | Use of s-erbb-3 as a marker for cancer |
| WO2010099186A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Her2 antibody compositions |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| AU2010273319B2 (en) | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
| SI2462158T1 (en) | 2009-08-06 | 2018-04-30 | F. Hoffmann-La Roche Ag | Method to improve virus removal in protein purification |
| WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
| CA2771744A1 (en) | 2009-08-21 | 2011-02-24 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
| EP2475390A4 (en) | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
| BR112012007760A2 (pt) | 2009-10-07 | 2015-08-25 | Macrogenics Inc | Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo |
| EP2486052A4 (en) | 2009-10-09 | 2013-05-01 | Merck Sharp & Dohme | GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES |
| WO2011047180A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| PL2719708T3 (pl) | 2009-11-13 | 2018-04-30 | Daiichi Sankyo Europe Gmbh | Materiał i sposoby leczenia lub zapobiegania chorobom związanym z HER-3 |
| WO2011103242A1 (en) | 2010-02-18 | 2011-08-25 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| US20130225424A1 (en) | 2010-03-03 | 2013-08-29 | Targeted Molecular Diagnostics, Llc | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| WO2011139629A2 (en) | 2010-04-26 | 2011-11-10 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
| WO2011143414A1 (en) | 2010-05-13 | 2011-11-17 | Fox Chase Cancer Center | RECOMBINANTLY PRODUCED ANTIBODIES TARGETING ErbB SIGNALING MOLECULES AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| SG185354A1 (en) | 2010-05-20 | 2012-12-28 | Ablynx Nv | Biological materials related to her3 |
| WO2012103341A1 (en) | 2011-01-27 | 2012-08-02 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-erbb3 antibodies |
| CN103649117B (zh) | 2011-02-04 | 2016-09-14 | 霍夫曼-拉罗奇有限公司 | Fc变体及其生成方法 |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| JP6228014B2 (ja) | 2011-02-07 | 2017-11-08 | リサーチ ディベロップメント ファウンデーション | 操作された免疫グロブリンＦｃポリペプチド |
| JP2014509850A (ja) | 2011-03-06 | 2014-04-24 | メルク セロノ ソシエテ アノニム | 低フコース細胞株およびその使用 |
| AU2012229102B2 (en) | 2011-03-17 | 2016-02-04 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
-
2011
- 2011-09-01 TW TW100131536A patent/TW201302793A/zh unknown
- 2011-09-02 JP JP2013527341A patent/JP2013544492A/ja active Pending
- 2011-09-02 EA EA201390328A patent/EA201390328A1/ru unknown
- 2011-09-02 MX MX2013002535A patent/MX2013002535A/es unknown
- 2011-09-02 NZ NZ607680A patent/NZ607680A/en not_active IP Right Cessation
- 2011-09-02 PH PH1/2013/500353A patent/PH12013500353A1/en unknown
- 2011-09-02 SG SG2013013057A patent/SG187930A1/en unknown
- 2011-09-02 KR KR1020137008415A patent/KR20130101047A/ko not_active Withdrawn
- 2011-09-02 CN CN2011800533015A patent/CN103189391A/zh active Pending
- 2011-09-02 MA MA35784A patent/MA34555B1/fr unknown
- 2011-09-02 WO PCT/US2011/050322 patent/WO2012031198A2/en not_active Ceased
- 2011-09-02 SG SG10201401681PA patent/SG10201401681PA/en unknown
- 2011-09-02 BR BR112013005242A patent/BR112013005242A2/pt not_active IP Right Cessation
- 2011-09-02 US US13/639,918 patent/US9085622B2/en active Active
- 2011-09-02 PE PE2013000314A patent/PE20140133A1/es not_active Application Discontinuation
- 2011-09-02 AU AU2011295726A patent/AU2011295726B2/en not_active Ceased
- 2011-09-02 EP EP11822713.1A patent/EP2611829A4/en not_active Withdrawn
- 2011-09-02 CA CA2809443A patent/CA2809443A1/en not_active Abandoned
- 2011-09-05 UY UY0001033591A patent/UY33591A/es unknown
-
2013
- 2013-02-27 CL CL2013000566A patent/CL2013000566A1/es unknown
- 2013-03-13 CO CO13050512A patent/CO6690769A2/es unknown
- 2013-03-20 CR CR20130128A patent/CR20130128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2013000566A1 (es) | 2014-01-24 |
| EP2611829A2 (en) | 2013-07-10 |
| AU2011295726B2 (en) | 2014-11-06 |
| AU2011295726A1 (en) | 2013-03-21 |
| EP2611829A4 (en) | 2014-05-07 |
| WO2012031198A3 (en) | 2012-05-18 |
| EA201390328A1 (ru) | 2013-08-30 |
| NZ607680A (en) | 2015-02-27 |
| MA34555B1 (fr) | 2013-09-02 |
| TW201302793A (zh) | 2013-01-16 |
| MX2013002535A (es) | 2013-06-03 |
| PE20140133A1 (es) | 2014-02-09 |
| US20130156779A1 (en) | 2013-06-20 |
| SG10201401681PA (en) | 2014-07-30 |
| CR20130128A (es) | 2013-06-28 |
| UY33591A (es) | 2012-03-30 |
| CO6690769A2 (es) | 2013-06-17 |
| WO2012031198A2 (en) | 2012-03-08 |
| CN103189391A (zh) | 2013-07-03 |
| SG187930A1 (en) | 2013-03-28 |
| CA2809443A1 (en) | 2012-03-08 |
| BR112013005242A2 (pt) | 2016-06-28 |
| US9085622B2 (en) | 2015-07-21 |
| PH12013500353A1 (en) | 2013-03-25 |
| JP2013544492A (ja) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130101047A (ko) | 신규한 항원 결합 단백질 | |
| JP7062704B2 (ja) | アゴニスト性ｉｃｏｓ結合タンパク質 | |
| WO2016059602A2 (en) | Methods of treating cancer and related compositions | |
| US20190256599A1 (en) | Anti-icos and anti-pd-1 antibody combination therapy | |
| KR20140130749A (ko) | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 | |
| AU2017204686B2 (en) | Compositions and methods for detecting and treating esophageal cancer | |
| US20230295313A1 (en) | Il1rap binding proteins | |
| TWI873112B (zh) | 與TfR結合之雙專一性抗體 | |
| CA3151078A1 (en) | Anti-il-27 antibodies and uses thereof | |
| CN116940597A (zh) | 多特异性抗体及其用途 | |
| TWI907249B (zh) | 與TfR結合之雙專一性抗體 | |
| HK40014509A (en) | Icos binding proteins | |
| HK40016303A (en) | Icos binding proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130402 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |